US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks

As the U.S. stock market continues to reach new heights, with the S&P 500 and Nasdaq hitting record levels driven by gains in technology stocks, investors are increasingly exploring diverse opportunities across different sectors. Penny stocks, though often considered a relic of past market eras, remain an intriguing area for those looking to uncover growth potential at lower price points. These smaller or newer companies can offer significant value when they possess strong balance sheets and solid fundamentals, presenting a chance for upside while mitigating some of the typical risks associated with this segment.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.80	$5.81M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.62	$2.03B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$136.98M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2408	$8.86M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.59	$52.47M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.81	$142.8M	★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9429	$84.8M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.87	$413.23M	★★★★☆☆

Click here to see the full list of 708 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

LiveOne (NasdaqCM:LVO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: LiveOne, Inc. is a digital media company focused on acquiring, distributing, and monetizing live music, Internet radio, podcasting/vodcasting, and music-related streaming and video content with a market cap of $95.67 million.

Operations: The company's revenue is derived from its Media segment at $7.63 million, Slacker at $72.73 million, and PodcastOne at $47.46 million.

Market Cap: $95.67M

LiveOne, Inc., with a market cap of US$95.67 million, faces challenges typical for penny stocks, such as high volatility and recent shareholder dilution. Despite being unprofitable, it has reduced losses over the past five years and maintains a positive cash flow runway exceeding three years. However, LiveOne's Nasdaq listing is at risk due to non-compliance with the minimum bid price rule; it has until May 2025 to rectify this issue or face potential delisting. Recent strategic partnerships and earnings guidance adjustments reflect efforts to enhance revenue streams and shareholder value amidst ongoing financial pressures.

• Unlock comprehensive insights into our analysis of LiveOne stock in this financial health report.
• Review our growth performance report to gain insights into LiveOne's future.

Generation Bio (NasdaqGS:GBIO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Generation Bio Co. develops non-viral genetic medicines for treating rare and prevalent diseases, with a market cap of approximately $101.53 million.

Operations: The company's revenue segment is Pharmaceuticals, generating $18.58 million.

Market Cap: $101.53M

Generation Bio Co., with a market cap of US$101.53 million, remains pre-revenue and unprofitable, reflecting typical challenges for penny stocks. The company has no debt and maintains a stable cash runway exceeding two years, which is crucial given its ongoing development in non-viral genetic medicines. Recent presentations highlighted promising advancements in their ctLNP and iqDNA platforms, showcasing potential therapeutic breakthroughs. However, the stock experiences high volatility and reported increased net losses over the past year despite reducing quarterly losses compared to last year. These factors underscore both opportunities and risks inherent in investing at this stage.

• Take a closer look at Generation Bio's potential here in our financial health report.
• Evaluate Generation Bio's prospects by accessing our earnings growth report.

Relmada Therapeutics (NasdaqGS:RLMD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Relmada Therapeutics, Inc. is a clinical-stage biotechnology company that develops products for treating central nervous system diseases and other disorders in the United States, with a market cap of $91.13 million.

Operations: Relmada Therapeutics, Inc., a clinical-stage biotechnology firm focused on developing treatments for central nervous system disorders in the United States, does not currently report any revenue segments.

Market Cap: $91.13M

Relmada Therapeutics, with a US$91.13 million market cap, is pre-revenue and unprofitable, common among penny stocks. The company has no debt and its short-term assets significantly exceed liabilities, providing some financial stability despite a cash runway of less than a year if current cash flow trends persist. Recent developments include the initiation of dosing in a Phase 1 study for REL-P11, indicating progress in their pipeline for metabolic diseases. Although net losses have decreased slightly year-over-year, earnings are forecast to decline over the next three years, highlighting ongoing financial challenges amidst potential opportunities.

• Navigate through the intricacies of Relmada Therapeutics with our comprehensive balance sheet health report here.
• Understand Relmada Therapeutics' earnings outlook by examining our growth report.

Taking Advantage

• Click this link to deep-dive into the 708 companies within our US Penny Stocks screener.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com